Scinai Immunotherapeutics (SCNI) Operating Leases (2019 - 2025)

Scinai Immunotherapeutics has disclosed Operating Leases across 7 years of filings, most recently posting $3.1 million for Q4 2025.

• Operating Leases for Q4 2025 came in at $3.1 million, up 122.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.1 million (up 122.82% YoY), and the FY2025 annual result was $3.1 million, up 122.82% from the prior year.
• Operating Leases came in at $3.1 million for Q4 2025 at Scinai Immunotherapeutics, up from $1.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $3.1 million in Q4 2025 to a low of $343000.0 in Q4 2023.
• The 5-year median for Operating Leases is $777500.0 (2023), against an average of $1.0 million.
• Across the five-year window, Operating Leases plunged 75.73% in 2022 and surged 308.75% in 2024, its largest moves.
• Scinai Immunotherapeutics' Operating Leases stood at $1.4 million in 2021, then slumped by 75.73% to $351000.0 in 2022, then decreased by 2.28% to $343000.0 in 2023, then jumped by 308.75% to $1.4 million in 2024, then soared by 122.82% to $3.1 million in 2025.
• The last three Operating Leases figures came in at $3.1 million (Q4 2025), $1.6 million (Q2 2025), and $1.4 million (Q4 2024), per Business Quant data.